Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent anion channel 1 (VDAC1) has been identified as a key host cell surface receptor mediating the entry of Newcastle Disease Virus (NDV), including the highly virulent Italien strain (PubMed). While NDV initially attaches to sialic acid-containing glycoconjugates via its Hemagglutinin-Neuraminidase (HN) protein, the subsequent interaction with VDAC1 is crucial for viral internalisation and infection (PubMed). VDAC1 is a pore-forming protein primarily known for its role in the outer mitochondrial membrane, where it regulates the exchange of metabolites and ions between the mitochondria and the cytosol (UniProt). However, its presence on the plasma membrane allows it to serve as a gateway for certain viruses. The Italien strain, a velogenic form of NDV, causes severe respiratory and neurological disease in poultry, making the HN-VDAC1 interaction a significant target for antiviral development (NCBI). Experimental inhibitors like VBIT-4, which target VDAC1, have demonstrated the ability to block NDV entry, although the protein's essential role in cellular metabolism and apoptosis presents challenges for systemic therapeutic use (PubMed).
Inhibition of VDAC1 prevents its interaction with the viral Hemagglutinin-Neuraminidase (HN) protein, thereby blocking viral entry; alternatively, sialidases remove the primary attachment factor, sialic acid, to prevent viral binding.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion channel 1 (VDAC1) (VDAC1).